4P Pharma, SATT AxLR and IBMM have concluded a co-development agreement
Montpellier, December 1st 2015
In the context of an innovative medical drug development project for the treatment of cancers, called “Imiqualines”, the oncology-pharmaco-chemical and pharmaco-toxicological team of IBMM, SATT AxLR and 4P Pharma have concluded a co-development maturation agreement with a licensing option.
EN: Press release 4P Pharma-SATT AxLR 011215
FR: Communiqué de presse 4P Pharma-SATT AxLR 011215 Press release 4P Pharma-SATT AxLR 011215
PRESS CONTACTS:
4P Pharma
Revital Rattenbach
1 rue du Professeur Calmette, 59000 Lille
Tel: +33 (0)9 50 72 97 68
Université de Montpellier
Anne Delestre
CC 07-003 Place Eugène Bataillon, 34095 Montpellier cedex 5
Tel: +33 (0)4 34 43 31 93
CNRS
Aurélie Lieuvin
1919 route de Mende, 34293 Montpellier cedex 5
Tel: +33 (0)4 67 61 35 10
AxLR SATT
Franck-Léopold Erstein
1000, Avenue Agropolis, 34394 Montpellier cedex 5
Tel: +33 (0)6 07 28 21 43